SCHEMBL4829524

SCHEMBL4829524

COc1cnc2[nH]cc(-c3oncc3-c3cccc(Cl)c3Cl)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 2/20 0.42
KIT P10721 6/20 0.41
NEK1 Q96PY6 1/20 0.39
DYRK1A Q13627 3/20 0.39
NUDT1 P36639 1/20 0.39
CLK1 P49759 1/20 0.38
DYRK3 O43781 1/20 0.38
ROCK2 O75116 1/20 0.38
PRKD3 O94806 1/20 0.38
MAP4K4 O95819 1/20 0.38
LCK P06239 1/20 0.38
CDK1 P06493 1/20 0.38
FGFR1 P11362 1/20 0.38
RPS6KB1 P23443 1/20 0.38
MARK3 P27448 1/20 0.38
AXL P30530 1/20 0.38
FLT4 P35916 1/20 0.38
FLT3 P36888 1/20 0.38
SYK P43405 1/20 0.38
CSNK1D P48730 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4831176 0.84 DYRK1A (0.39) KITDYRK1ACLK1AXLJAK2
SCHEMBL4829343 0.83 RPS6KA5 (0.49) DYRK1AROCK2PRKD3MAP4K4CDK1
SCHEMBL4829375 0.83 DYRK1A (0.42) NTRK1KITNEK1DYRK1ACLK1
SCHEMBL8290894 0.81 RPS6KA5 (0.45) NTRK1KITDYRK1APRKD3MAP4K4
SCHEMBL4832756 0.79 NTRK1 (0.53) NTRK1KITNEK1DYRK1ACLK1
SCHEMBL8290062 0.77 PTPN11 (0.40) NUDT1
SCHEMBL8290891 0.76 IKBKE (0.35) DYRK1AROCK2PRKD3MAP4K4FLT3
SCHEMBL14382388 0.76 DYRK1B (0.35) NTRK1NEK1DYRK1ACLK1DYRK3
SCHEMBL4831389 0.73 DYRK1A (0.52) NTRK1KITNEK1DYRK1ACLK1
SCHEMBL4831120 0.72 RPS6KA5 (0.50) DYRK1AROCK2PRKD3MAP4K4CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7446199-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
US-7446199-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
US-7446199-B2 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-11-04 US disclosed
EP-1664043-B1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2007-11-14 EP disclosed
EP-1664043-B1 COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2007-11-14 EP disclosed
US-20050137201-A1 Compositions useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137201-A1 Compositions useful as inhibitors of protein kinases MAP3K20, PACSIN2, MAP3K6 NTRK1 1926/4885KIT 1325/4885NEK1 320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.